Hair dye use and prostate cancer risk: A prospective analysis in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort.
Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study
hair dye
prospective study
prostate cancer risk
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 03 2022
15 03 2022
Historique:
revised:
30
09
2021
received:
18
08
2021
accepted:
27
10
2021
pubmed:
20
11
2021
medline:
11
3
2022
entrez:
19
11
2021
Statut:
ppublish
Résumé
According to the International Agency for Research on Cancer, some hair dye chemicals are considered mutagenic and carcinogenic in humans. One hospital-based study reported a positive association between hair dye use and prostate cancer risk, but no prospective analyses have been conducted. This study investigated the association between hair dye use and prostate cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort, a large, well-characterized cohort of 29,133 male Finnish smokers. Participants completed questionnaires regarding lifestyle, medical, and risk factor information, including the use of hair dye, which was available for 98.8% of the cohort (28,795 men). Prostate cancer cases were identified through linkage with the Finnish Cancer Registry and the Finnish Mortality Register. Hazard ratios (HRs) and confidence intervals (CIs) were estimated via multivariable Cox proportional hazards regression. During a 28-year period of observation, 2703 incident prostate cancer cases were diagnosed. As reported at the baseline, 75 men used hair dye, and 13 of these men were subsequently diagnosed with prostate cancer. After adjustments for potential confounders, men who used hair dyes experienced substantially higher prostate cancer risk than men who did not (HR, 1.77; 95% CI, 1.03-3.05). This first prospective investigation of hair dye use and prostate cancer suggests that personal hair dye use may be related to increased risk. The findings warrant re-examination in other prospective cohorts along with studies evaluating specific hair dyes and possible underlying biological mechanisms.
Sections du résumé
BACKGROUND
According to the International Agency for Research on Cancer, some hair dye chemicals are considered mutagenic and carcinogenic in humans. One hospital-based study reported a positive association between hair dye use and prostate cancer risk, but no prospective analyses have been conducted.
METHODS
This study investigated the association between hair dye use and prostate cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort, a large, well-characterized cohort of 29,133 male Finnish smokers. Participants completed questionnaires regarding lifestyle, medical, and risk factor information, including the use of hair dye, which was available for 98.8% of the cohort (28,795 men). Prostate cancer cases were identified through linkage with the Finnish Cancer Registry and the Finnish Mortality Register. Hazard ratios (HRs) and confidence intervals (CIs) were estimated via multivariable Cox proportional hazards regression.
RESULTS
During a 28-year period of observation, 2703 incident prostate cancer cases were diagnosed. As reported at the baseline, 75 men used hair dye, and 13 of these men were subsequently diagnosed with prostate cancer. After adjustments for potential confounders, men who used hair dyes experienced substantially higher prostate cancer risk than men who did not (HR, 1.77; 95% CI, 1.03-3.05).
CONCLUSIONS
This first prospective investigation of hair dye use and prostate cancer suggests that personal hair dye use may be related to increased risk. The findings warrant re-examination in other prospective cohorts along with studies evaluating specific hair dyes and possible underlying biological mechanisms.
Identifiants
pubmed: 34797564
doi: 10.1002/cncr.34035
pmc: PMC8882135
mid: NIHMS1754686
doi:
Substances chimiques
Hair Dyes
0
beta Carotene
01YAE03M7J
alpha-Tocopherol
H4N855PNZ1
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1260-1266Subventions
Organisme : NCI NIH HHS
ID : HHSN261201000006C
Pays : United States
Organisme : NIH HHS
Pays : United States
Organisme : CCR NIH HHS
ID : N01RC37004
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA CP010221
Pays : United States
Organisme : NCI NIH HHS
ID : N01 CN045165
Pays : United States
Informations de copyright
© 2021 American Cancer Society.
Références
J Clin Oncol. 2015 Feb 10;33(5):419-25
pubmed: 25225425
Int J Urol. 2003 Mar;10(3):167-73
pubmed: 12622714
Int J Dermatol. 2006 Mar;45(3):323-6
pubmed: 16533241
Acta Oncol. 2002;41(4):381-8
pubmed: 12234031
Ann Epidemiol. 2014 Feb;24(2):151-9
pubmed: 24342029
Int J Cancer. 2015 Nov 1;137(9):2124-32
pubmed: 25904191
Occup Environ Med. 2010 May;67(5):351-8
pubmed: 20447989
Int J Epidemiol. 2009 Dec;38(6):1512-31
pubmed: 19755396
J Clin Chem Clin Biochem. 1984 Mar;22(3):245-51
pubmed: 6327876
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
JAMA. 2005 May 25;293(20):2516-25
pubmed: 15914752
Int J Cancer. 2020 Jul 15;147(2):383-391
pubmed: 31797377
Int J Toxicol. 2018 Sep/Oct;37(2_suppl):61S-94S
pubmed: 30235959
Clin Chem. 1986 May;32(5):874-6
pubmed: 3084131
Natl Cancer Inst Carcinog Tech Rep Ser. 1978;84:1-141
pubmed: 12830214
Cancer Med. 2017 Oct;6(10):2471-2486
pubmed: 28925101
Food Chem Toxicol. 2004 Apr;42(4):517-43
pubmed: 15019177
IARC Monogr Eval Carcinog Risks Hum. 1993;57:7-398
pubmed: 7911535
Cancer Causes Control. 2011 Nov;22(11):1545-52
pubmed: 21915616
Int J Hyg Environ Health. 2017 Jul;220(5):849-856
pubmed: 28420543
Anticancer Res. 2018 Feb;38(2):707-716
pubmed: 29374694
Environ Sci Pollut Res Int. 2017 Feb;24(4):3298-3314
pubmed: 27826822
Contact Dermatitis. 2005 Jul;53(1):40-5
pubmed: 15982231
Int J Epidemiol. 1985 Dec;14(4):549-54
pubmed: 4086141
Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1850-60
pubmed: 21784952
J Natl Cancer Inst. 2009 Sep 16;101(18):1272-9
pubmed: 19700655
IARC Monogr Eval Carcinog Risks Hum. 2010;99:1-658
pubmed: 21528837
J Am Acad Dermatol. 2013 Jun;68(6):937-43
pubmed: 23395589
Medicine (Baltimore). 2018 Jul;97(28):e11379
pubmed: 29995779
Carcinogenesis. 1999 Aug;20(8):1591-5
pubmed: 10426812
Cancer Res. 2019 Jan 1;79(1):274-285
pubmed: 30425058
Am J Epidemiol. 2011 Apr 1;173(7):813-21
pubmed: 21389041
Urol Oncol. 2018 Feb;36(2):80.e7-80.e15
pubmed: 29054497
Endocrine. 1998 Aug;9(1):105-11
pubmed: 9798737
BMC Cancer. 2016 Mar 21;16:242
pubmed: 26996776
Ann Epidemiol. 1994 Jan;4(1):1-10
pubmed: 8205268
Int J Cancer. 2011 Dec 15;129(12):2894-904
pubmed: 21678399
Pharmacogenetics. 2003 Mar;13(3):159-67
pubmed: 12618593
PLoS One. 2021 Feb 4;16(2):e0243792
pubmed: 33539348